Insulet Corporation $PODD Shares Purchased by Headlands Technologies LLC

Key Points

• Headlands Technologies LLC increased its Insulet stake by 2,041.5% in the second quarter, owning 31,930 shares valued at approximately $4.86 million.
• Insulet reported strong quarterly results, with revenue up 23.5% year over year to $801.7 million and EPS of $1.66, exceeding the $1.47 consensus estimate.
• Despite solid fundamentals, analyst sentiment remains cautious: Insulet has a consensus “Hold” rating, with an average price target of $195.40, while securities litigation related to Omnipod product corrections creates additional risk.

Headlands Technologies LLC lifted its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 2,041.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 31,930 shares of the medical instruments supplier's stock after purchasing an additional 30,439 shares during the quarter. Headlands Technologies LLC's holdings in Insulet were worth $4,861,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of PODD. Larson Financial Group LLC increased its stake in Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier's stock valued at $25,000 after purchasing an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Insulet during the fourth quarter worth $26,000. Elyxium Wealth LLC purchased a new stake in shares of Insulet during the fourth quarter valued at $28,000. DV Equities LLC purchased a new stake in shares of Insulet during the fourth quarter valued at $28,000. Finally, MV Capital Management Inc. acquired a new position in shares of Insulet in the 4th quarter valued at $29,000.

Insider Activity at Insulet

In other news, Director Timothy C. Stonesifer bought 2,790 shares of the business's stock in a transaction dated Wednesday, June 3rd. The stock was purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the acquisition, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.36% of the stock is owned by insiders.

Insulet Price Performance

Shares of PODD opened at $145.13 on Monday. Insulet Corporation has a 52 week low of $126.40 and a 52 week high of $354.88. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $10.06 billion, a price-to-earnings ratio of 27.13, a PEG ratio of 1.14 and a beta of 1.10. The stock's 50-day moving average price is $154.46 and its 200-day moving average price is $180.69.

Insulet (NASDAQ:PODD - Get Free Report) last posted its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, topping the consensus estimate of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The firm had revenue of $801.70 million for the quarter, compared to analyst estimates of $787.39 million. During the same period last year, the company earned $1.17 earnings per share. Insulet's revenue for the quarter was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, sell-side analysts predict that Insulet Corporation will post 6.51 EPS for the current year.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s latest reported quarter showed strong fundamentals: revenue rose 23.5% year over year to $801.7 million, while adjusted earnings of $1.66 per share exceeded the $1.47 analyst consensus. The company has also issued fiscal 2026 earnings guidance, with analysts projecting approximately $6.51 per share. Insulet financial and trading information
• Neutral Sentiment: Multiple law firms—including Rosen, Bragar Eagel & Squire, Bronstein Gewirtz & Grossman, Faruqi & Faruqi, and Robbins Geller—reminded investors that August 31, 2026 is the deadline to seek lead-plaintiff status in the securities class action. The notices generally cover purchases made between February 21, 2025 and May 26, 2026, although one complaint cites a later starting date of May 21, 2025. Rosen Insulet deadline notice
• Negative Sentiment: The litigation creates an overhang because investors allege Insulet and certain officers violated federal securities laws and seek damages. The notices reference two Omnipod medical-device corrections and a decline of more than $90 per share from pre-disclosure levels, potentially increasing concerns about product quality, disclosure practices, legal costs, and reputational risk. The allegations have not been proven. Insulet investor litigation alert

Analysts Set New Price Targets

A number of analysts have commented on PODD shares. JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a $152.00 price target (down from $275.00) on shares of Insulet in a research report on Thursday, August 6th. Bank of America reduced their price objective on Insulet from $288.00 to $208.00 and set a "buy" rating for the company in a research note on Monday, May 18th. Evercore set a $180.00 target price on Insulet in a report on Monday, July 6th. Truist Financial reiterated a "hold" rating and issued a $153.00 target price (down from $210.00) on shares of Insulet in a research report on Wednesday, August 5th. Finally, BTIG Research downgraded shares of Insulet from a "buy" rating to a "neutral" rating in a report on Thursday, August 6th. Fourteen equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Insulet currently has an average rating of "Hold" and a consensus target price of $195.40.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source